Vre

Vancomycin-Resistant Enterococcus

  • Vancomycin

    Vancomycin was first discovered in 1953 by Edmund Kornfield from a soil sample from the jungles in Borenl by isolating the large glycopeptide chemical structure.
  • Medical Advancements

    Vancomycin was first avaliable to the public, but the medicina tarnished quickly because of the impurities in fermentation and preparation which was linked to ototoxicity and nephrotoxicity.
  • Enterococcal

    http://youtu.be/y6UqRJmjGqA
    In 1984 bateria Enterococcal was first indentified.
  • VRE first outbreak in Europe

    During the mid 1980's, severaal outbreaks of VRE were found in Italy , Sweden, and other Northern European countries.
    Vancomycin-Resistant Enterococcus is a bacteria that is called Enterococcus. This bacteria has developed to be resistant toward many antibiotics.
  • VRE found in U.S.A

    At the begining of 1988 VRE was discovered in Georgia Atlanta.
  • Period: to

    High percentage of VRE

    During these years the percentage of infected people rose in the United States from .03% to 7.9%
  • Period: to

    Outbreak at the Akdeniz University Hospital in Turkey

    The outbreak was caused by van-A positve enterococci phenotype. Then 20 vancomycin ressistant enterococcus faecium isolates were seperated from 5 other different infected patients. Two patients died from severe enterococcal infections.
  • German University Hospital

    5 colonized patients were identified with VRE.
  • Germany

    In the same University Hospital in Germany 8 patients were diagnosed with VRE.
  • Gemany Infection Control Program

    Due to the anal/rectum stool samples a large increase of patients infected rosed from 48 to 105 patients.
  • Hong Kong

    Three patients were identified in
  • Queen Elizabeth Hospital

    Queen Elizabeth Hospital located in Yau Ma Tei was one of the worst cases. Throughout the hospital, 300 patients were detected with Vancomycin-Resistant Enterococcus.
  • NanoMedicine Discoveries

    Multidrug resistant microbes or “superbugs” are resistant to vancomycin because of an alteration of their cell wall structure. Vancomycin-Resistant Enterococcus (VRE), now is the second leading superbug in US hospitals and responsible for urine, heart, wound and blood infections. In the field of nanomedicine, the first biodegradable polymer-based nanoparticle is capable of combating multidrug-resistant microbes, which works by selectively targeting and tearing down bacterial cell walls and membr